Aplastic Anemia As a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow
Overview
Chemistry
Molecular Biology
Authors
Affiliations
In recent years, it has become increasingly apparent that bone marrow (BM) failures and myeloid malignancy predisposition syndromes are characterized by a wide phenotypic spectrum and that these diseases must be considered in the differential diagnosis of children and adults with unexplained hematopoiesis defects. Clinically, hypocellular BM failure still represents a challenge in pathobiology-guided treatment. There are three fundamental topics that emerged from our review of the existing data. An exogenous stressor, an immune defect, and a constitutional genetic defect fuel a vicious cycle of hematopoietic stem cells, immune niches, and stroma compartments. A wide phenotypic spectrum exists for inherited and acquired BM failures and predispositions to myeloid malignancies. In order to effectively manage patients, it is crucial to establish the right diagnosis. New theragnostic windows can be revealed by exploring BM failure pathomechanisms.
Park S World J Stem Cells. 2024; 16(11):900-905.
PMID: 39619872 PMC: 11606349. DOI: 10.4252/wjsc.v16.i11.900.
Piekarska A, Pawelec K, Szmigielska-Kaplon A, Ussowicz M Front Immunol. 2024; 15:1378432.
PMID: 38646536 PMC: 11026616. DOI: 10.3389/fimmu.2024.1378432.
Drug Design and Development for Rare Hematologic Diseases.
Fattizzo B, Capecchi M, Motta I Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895940 PMC: 10609818. DOI: 10.3390/ph16101469.
Perspective and Experience of Patients with Aplastic Anemia on Medication Adherence.
Li H, Wu X, Shen J, Lou S Patient Prefer Adherence. 2023; 17:2215-2225.
PMID: 37701429 PMC: 10493145. DOI: 10.2147/PPA.S390409.
Berrada S, Martinez-Balsalobre E, Larcher L, Azzoni V, Vasquez N, Da Costa M Nucleic Acids Res. 2023; 51(15):7988-8004.
PMID: 37395445 PMC: 10450163. DOI: 10.1093/nar/gkad559.